secwatch / observer
8-K filed April 20, 2026, 7:59 PM ET ticker ANAB CIK 0001370053
other confidence high sentiment neutral materiality 0.85

AnaptysBio completes spin-off of First Tracks Biotherapeutics (TRAX); distribution effective April 20, 2026

ANAPTYSBIO, INC

item 1.01item 2.01item 5.02item 8.01item 9.01

Machine-readable event card

schema_version
secwatch.filing_event.v1
accession
0001193125-26-164330
form_type
8-K
ticker
ANAB
cik
0001370053
company_name
ANAPTYSBIO, INC
filed_at
2026-04-20T23:59:59+00:00
discovered_at
2026-05-14T18:02:32.199577+00:00
generated_at
2026-05-15T05:17:44.795239+00:00
sec_items
["1.01", "2.01", "5.02", "8.01", "9.01"]
event_type
other
sentiment
neutral
materiality_score
0.85
calibrated_materiality_score
0.85
confidence
high
secwatch_canonical_url
https://secwatch.observer/filing/0001193125-26-164330
json_url
https://secwatch.observer/filing/0001193125-26-164330.json
markdown_url
https://secwatch.observer/filing/0001193125-26-164330.md
text_url
https://secwatch.observer/filing/0001193125-26-164330.txt
edgar_index_url
https://www.sec.gov/Archives/edgar/data/1370053/000119312526164330/0001193125-26-164330-index.htm
edgar_primary_document_url
https://www.sec.gov/Archives/edgar/data/1370053/000119312526164330/d120122d8k.htm
generated_by_model
deepseek-v4-flash:cloud@v2
review_status
machine_generated
human_reviewed
false
corrected
false
correction_note
null
correction_timestamp
null
superseded_by
null
JSON Markdown Plain text

Source-grounded claims

08637338127a5c4c1dbd16f992c88b4733ff84be

ANAPTYSBIO, INC completed a disposition involving First Tracks Biotherapeutics, Inc. (closed 2026-04-20).

completed the previously announced separation (the "Spin-Off") of First Tracks Biotherapeutics, Inc. ("First Tracks Biotherapeutics") from the Company

SEC 8-K Item 2.01/5.01 confidence 0.95 SEC evidence

a2153f97566840838e5f6f6ce279a91de4d69d07

ANAPTYSBIO, INC entered into Separation and Distribution Agreement with First Tracks Biotherapeutics valued at $100.0 million.

the Company and First Tracks Biotherapeutics entered into a separation and distribution agreement (the “Separation and Distribution Agreement”)

SEC 8-K Item 1.01/1.02 confidence 0.9 SEC evidence

Comparable filings

EWCZ

European Wax Center completes take-private by General Atlantic at $5.80/share; stock delisted

European Wax Center, Inc. May 8, 2026, 7:59 PM ET m_and_a Items 1.01, 1.02, 2.01, 2.03, 3.01, 3.03, 5.02, 5.03, 5.01, 8.01, 9.01

same fact type: ma_transaction, material_agreement same SEC item: 1.01, 2.01, 5.02, 8.01, 9.01 similar materiality

This filing

completed the previously announced separation (the "Spin-Off") of First Tracks Biotherapeutics, Inc. ("First Tracks Biotherapeutics") from the Company

Comparable filing

excluded shares pursuant to the terms of the Merger Agreement, was cancelled and extinguished and automatically converted into the right to receive an amount in cash equal to $5.80 per share of Class A Common Stock, without interest thereon (the “ Class A Per Share Price ”), (ii) each share of the Company’s Class B common stock, par value $0.00001 per share

Filing page SEC filing

SSM

Sono Group exits solar: sells Sono Motors and €10.5M loan to management for €1 each

Sono Group N.V. May 8, 2026, 7:59 PM ET m_and_a Items 2.05, 1.01, 2.01, 8.01, 9.01

same fact type: ma_transaction, material_agreement same SEC item: 1.01, 2.01, 8.01, 9.01 similar materiality

This filing

completed the previously announced separation (the "Spin-Off") of First Tracks Biotherapeutics, Inc. ("First Tracks Biotherapeutics") from the Company

Comparable filing

true 0001840416 0001840416 2026-05-04 2026-05-04 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 __________________________ FORM 8-K/A (Amendment No. 1) __________________________ CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 4, 2026

Filing page SEC filing

SHPH

Shuttle Pharma completes merger with United Dogecoin, pivots to crypto, raises $9.55M PIPE

Shuttle Pharmaceuticals Holdings, Inc. May 7, 2026, 7:59 PM ET m_and_a Items 1.01, 2.01, 3.02, 3.03, 5.02, 5.03, 9.01

same fact type: ma_transaction, material_agreement same SEC item: 1.01, 2.01, 5.02, 9.01 similar materiality

This filing

completed the previously announced separation (the "Spin-Off") of First Tracks Biotherapeutics, Inc. ("First Tracks Biotherapeutics") from the Company

Comparable filing

On May 6, 2026 (the “ Closing Date ”), Shuttle Pharmaceuticals Holdings, Inc., a Delaware corporation (“ Shuttle ” or “ Acquiror ”), completed its previously announced merger pursuant to an Agreement and Plan of Merger (the “ Merger Agreement ”), entered into on April 30, 2026 by and among the Acquiror, Shuttle Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Shuttle (“ Merger Sub ”) and United Dogecoin Inc., a Delaware corporation (the “ Company ”).

Filing page SEC filing

OCFC

OceanFirst closes acquisition of Flushing Financial; issues shares to Warburg Pincus

OCEANFIRST FINANCIAL CORP June 1, 2026, 5:19 PM ET m_and_a Items 1.01, 3.02, 2.01, 2.03, 3.03, 5.02, 5.03, 7.01, 9.01

same fact type: ma_transaction same SEC item: 1.01, 2.01, 5.02, 9.01 similar materiality

This filing

completed the previously announced separation (the "Spin-Off") of First Tracks Biotherapeutics, Inc. ("First Tracks Biotherapeutics") from the Company

Comparable filing

of Flushing (“ Flushing Common Stock ”) issued and outstanding immediately prior to the Effective Time, subject to certain exceptions, was converted into the right to receive 0.85 of a share (the “ Exchange Ratio ”) of common stock, par value $0.01 per share, of OceanFirst (“ OceanFirst Common Stock ” and such consideration, the “ Merger Consideration ”).

Filing page SEC filing

Enviri II Corp

New Enviri completes spin-off; starts trading June 2 under NVRI; ~$1.2B revenue, ~$140M EBITDA

Enviri II Corp June 1, 2026, 5:18 PM ET m_and_a Items 1.01, 2.03, 3.03, 5.03, 5.01, 5.02, 5.05, 7.01, 9.01

same fact type: ma_transaction, material_agreement same SEC item: 1.01, 5.02, 9.01 similar materiality

This filing

completed the previously announced separation (the "Spin-Off") of First Tracks Biotherapeutics, Inc. ("First Tracks Biotherapeutics") from the Company

Comparable filing

This Current Report on Form 8-K is being filed in connection with the completion of the spin-off of New Enviri contemplated by the Separation Agreement.

Filing page SEC filing

DGAC

Disciplined Growth Acquisition Corp. closes $150M IPO on NYSE

DISCIPLINED GROWTH ACQUISITION Corp June 1, 2026, 4:15 PM ET other_material Items 1.01, 3.02, 5.02, 5.03, 8.01, 9.01

same fact type: material_agreement same SEC item: 1.01, 5.02, 8.01, 9.01 similar materiality

This filing

the Company and First Tracks Biotherapeutics entered into a separation and distribution agreement (the “Separation and Distribution Agreement”)

Comparable filing

A Share Rights Agreement, dated May 26, 2026, by and between the Company and Odyssey Transfer and Trust Company, as rights agent

Filing page SEC filing

RPAY

REPAY closes $372M acquisition of KUBRA, funded with new $500M term loan

Repay Holdings Corp June 1, 2026, 4:14 PM ET m_and_a Items 1.01, 2.01, 1.02, 9.01, 2.03, 7.01

same fact type: ma_transaction, material_agreement same SEC item: 1.01, 2.01, 9.01 similar materiality

This filing

completed the previously announced separation (the "Spin-Off") of First Tracks Biotherapeutics, Inc. ("First Tracks Biotherapeutics") from the Company

Comparable filing

KUBRA became an indirect wholly owned subsidiary of the Company. Pursuant to the Purchase Agreement, the aggregate cash purchase price for the Acquisition was approximately $372 million, subject to customary post-closing adjustments. The closing cash consideration was funded with a combination of cash on hand and borrowings under the Credit Agreement described

Filing page SEC filing

APAD

Enhanced Group completes de-SPAC merger with Enhanced Ltd; redemptions of $201.7M

Enhanced Group Inc. May 8, 2026, 7:59 PM ET m_and_a Items 1.01, 2.01, 5.06, 3.02, 9.01, 4.01, 3.01, 3.03, 5.01, 5.02, 5.03, 5.05, 7.01

same fact type: ma_transaction same SEC item: 1.01, 2.01, 5.02, 9.01 similar materiality

This filing

completed the previously announced separation (the "Spin-Off") of First Tracks Biotherapeutics, Inc. ("First Tracks Biotherapeutics") from the Company

Comparable filing

On May 7, 2026, as contemplated by the Business Combination Agreement and as described in the section titled “ The BCA Proposal ” beginning on pa ge 180 of the Proxy Statement/Prospectus, the Company, Enhanced and Merger Sub consummated the business combination contemplated by the Business Combination Agreement, whereby: • Merger Sub merged with and into Enhanced (the “First Merger”), with Enhanced surviving the merger as a wholly owned subsidiary of the Company;

Filing page SEC filing

Source: SEC EDGAR
accession 0001193125-26-164330
view filing index on sec.gov
view primary document

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.